Clinical trials: Androgenic Alopecia
Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia.
- Trial name
- NCT01231607
- Testing
- 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride
- Where
- 39 sites in Argentina, Chile and 7 more
- Volunteers
- 917 people
- Sponsor
- GlaxoSmithKline
Androgenetic Alopecia
Treatment of Androgenetic Alopecia in Males and Females
The purpose of this study is to evaluate the efficacy of Low Level Laser and Light Therapy system configured in a novel product called the TopHat 655 system, for promoting hair growth in males and females diagnosed with…
- Trial name
- LLLT (NCT01437163)
- Testing
- TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Apira Science, Inc.
Androgenetic Alopecia, AGA
Efficacy and Safety of VDPHL01 in Males With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06724614
- Testing
- VDPHL01
- Where
- 44 sites in United States
- Volunteers
- 480 people
- Sponsor
- Veradermics, Inc.
Alopecia, Androgenetic, Healthy
Assessment of Biological and Biometrological Parameters in Adult Subjects with Androgenetic Alopecia
Androgenetic alopecia is a chronic pathology affecting approximately 50% of men at 50 years old and is characterized by a progressive miniaturization of the hair follicle leading to a localized baldness.
- Trial name
- NCT06854432
- Testing
- Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Female Pattern Baldness
Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.
- Trial name
- GENERA (NCT05824065)
- Testing
- OMA102
- Where
- Brazil
- Volunteers
- 504 people
- Sponsor
- EMS
Androgenetic Alopecia
Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss.
- Trial name
- NCT06590779
- Testing
- Aminexil® active+ lotion, Finasteride 1mg
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Androgenetic Alopecia (AGA)
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06622824
- Testing
- KX-826 0.5% BID, KX-826 1.0% BID
- Where
- China
- Volunteers
- 756 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss).
- Trial name
- MINORA-MEN (NCT07529977)
- Testing
- Minoxidil oral solution
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Androgenetic Alopecia
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia.
- Trial name
- NCT07490327
- Testing
- AD-303A, AD-3031
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Moogene Medi Co., Ltd
Androgenetic Alopecia
Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application
This study is designed to explore the efficacy and safety of DA-4001 after topical application in male patients with androgenetic alopecia Design : Randomized, double-blind, active-controlled study Investigational Product …
- Trial name
- NCT02280603
- Testing
- DA-4001C, 5% minoxidil
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Dong-A ST Co., Ltd.
Androgenetic Alopecia
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
The study is designed to evaluate safety and efficacy of PP405 in adult female participants with androgenetic alopecia
- Trial name
- AWAKENING (NCT07907783)
- Testing
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Volunteers
- 200 people
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)
Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451190
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 9 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following…
- Trial name
- NCT04984707
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Alopecia, Androgenetic
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
- Trial name
- NCT05802173
- Testing
- TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Technoderma Medicines Inc.
Androgenetic Alopecia
Computer-Assisted Versus Manual Hair Harvest Comparative Study
The objective of this clinical study is to investigate and compare the safety and efficacy of the Restoration Robotics Computer-Assisted Harvesting System to the manual hair follicle harvesting method following a nine-month…
- Trial name
- NCT00926211
- Testing
- ARTAS™ System, Manual Hair Harvest
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Restoration Robotics, Inc.
Androgenetic Alopecia
Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia
This study will evaluate the skin pharmacokinetics and tolerability of bimatoprost Formulation A and Formulation B following 14 days of once daily topical administration in male participants with androgenetic alopecia (AGA).
- Trial name
- NCT02848300
- Testing
- Bimatoprost 1% Formulation A, Bimatoprost 1% Formulation B
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Allergan
Androgenetic Alopecia
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
- Trial name
- NCT06916793
- Testing
- CKD-843 dose#1, CKD-843 dose#2, Dutasteride Capsules
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Alopecia, Androgenetic, Baldness
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).
- Conditions
- Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)
- Trial name
- NEOPILI-2A (NCT07011485)
- Testing
- Minoxidil 5% Topical Solution, PDFE-2304 Topical Solution
- Where
- India
- Volunteers
- 15 people
- Sponsor
- PDFE Pharma Innovations FZCO
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
- Trial name
- NCT02279823
- Testing
- CB-03-01 solution, Minoxidil Solution 5%
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Intrepid Therapeutics, Inc.
Androgenetic Alopecia (AGA), Chronic Telogen Effluvium
Evaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair Loss
The goal of this study was to learn if dietary supplement in capsules and drinkable works to help hair loss in volunteers with chronic telogen effluvium and androgenetic alopecia and learn about its safety.
- Trial name
- NCT07358403
- Testing
- Dietary supplement capsule use for hair loss, Dietary supplement drinklable use for hair loss
- Where
- Italy
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Lacer S.A.